SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.

被引：0
|
作者：
Johnson, Geoffrey
Lengyelova, Eva
Nordquist, Luke T.
Prasad, Vikas
Anderson, Monique
Gervasio, Othon
Parker, Michelle
Miller, Robert M.
Sartor, A. Oliver
Tagawa, Scott T.
机构：
[1] Mayo Clin Rochester, Rochester, MN USA
[2] Clar Pharmaceut, Eveleigh, NSW, Australia
[3] Urol Canc Ctr PC, Omaha, NE USA
[4] Washington Univ, St Louis, MO USA
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-137-7318-7319; 613-615-646-3281-7408-2399; 261-492-2769; 283-183-180; 613-225-2577-2545; 283-2494; 283-183-180-5577-2829-12292; 6; 5; 4; 3; 2; 38092-23249;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS246
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS246 / TPS246
页数：1
相关论文
共 35 条
  • [21] A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer
    Chu, Franklin M.
    Picus, Joel
    Fracasso, Paula M.
    Dreicer, Robert
    Lang, Zhihui
    Foster, Brenda
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 674 - 679
  • [22] Randomized phase II study with window-design to evaluate anti-tumor activity of the survivin antisense oligonucleotide (ASO) ly2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC)
    Wiechno, Pawel J.
    Chlosta, Piotr
    Pikiel, Joanna
    Somer, Bradley G.
    Mellado, Begona
    Martinez, Ignacio Duran
    Castellano, Daniel E.
    Wedel, Steffen
    Grau, Jose Manuel Cervera
    Callies, Sophie
    Andre, Valerie
    Brown, Jacqueline
    Hurt, Karla
    Lahn, Michael M. F.
    Stoeckle, Michael
    Reuter, Christoph
    Heinrich, Bernhard
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
    Hyehyun Jeong
    Yong Sang Hong
    Jeong Eun Kim
    Hyeong-Seok Lim
    Joong Bae Ahn
    Sang Joon Shin
    Young Suk Park
    Seung Tae Kim
    Sae-Won Han
    Tae-You Kim
    Tae Won Kim
    Investigational New Drugs, 2021, 39 : 1335 - 1347
  • [24] A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
    Jeong, Hyehyun
    Hong, Yong Sang
    Kim, Jeong Eun
    Lim, Hyeong-Seok
    Ahn, Joong Bae
    Shin, Sang Joon
    Park, Young Suk
    Kim, Seung Tae
    Han, Sae-Won
    Kim, Tae-You
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1335 - 1347
  • [25] Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Azad, Arun
    Gurney, Howard
    Underhill, Craig
    Horvath, Lisa
    Voskoboynik, Mark
    Li, Xinghai
    King, Ivan
    Shao, Lisa
    Dai, Yiyun
    Perabo, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [26] An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika Paige
    Chu, Christina
    Richardson, Debra L.
    Arend, Rebecca Christian
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Hays, John L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT)in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
    Rosser, Charles Joel
    Hirasawa, Yosuke
    Acoba, Jared David
    Tamura, David Jon
    Pal, Sumanta K.
    Huang, Jeffrey
    Scholz, Mark C.
    Dorff, Tanya B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59-8862) in patients with taxane-resistant non-small cell lung cancer.
    Gurtler, JS
    Von Pawel, J
    Spiridonidis, CH
    Grossi, F
    Larriba, JL
    Moscovici, M
    Markovitz, E
    Voliotis, D
    Gottfried, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 650S - 650S
  • [29] ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Subudhi, Sumit Kumar
    Bendell, Johanna C.
    Carducci, Michael Anthony
    Kopp, Lisa M.
    Scott, Jennifer
    Grady, Michele M.
    Gardner, Olivia
    Wise, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
    Zhang, Wen
    Han, Xiaohong
    Yang, Lin
    Song, Yuanyuan
    Xie, Liangzhi
    Gai, Wenlin
    Wang, Yan
    Shi, Yuankai
    BMC CANCER, 2022, 22 (01)
1234